Neutrophil Extracellular Traps and Lupus Nephritis
NCT07721857 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2026-07-23
Summary
Lupus Nephritis is one of the most severe organ manifestations of systemic lupus erythematosus and represents a major cause of morbidity, chronic kidney disease, and long-term mortality. Despite significant advances in immunosuppressive therapies, a substantial proportion of patients fail to achieve sustained renal remission or progress to end-stage renal disease, highlighting the need for improved understanding of disease mechanisms and more reliable biomarkers for disease monitoring and therapeutic response
Conditions
- Lupus Nephritis (LN)
Interventions
- DIAGNOSTIC_TEST
-
Serum Neutrophil Extracellular Traps
Serum sample should be collected into a serum separator tube. After clotting for 2 hours at room temperature or overnight at 4°C, and then centrifuging at 1000 × g for 20 minutes. Assay freshly prepared serum immediately or store samples in aliquot at -20°C or -80°C for later use. Avoid repeated freeze-thaw cycles.
Sponsors & Collaborators
-
Assiut University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-09-01
- Primary Completion
- 2028-08-31
- Completion
- 2028-10-31
More Related Trials
-
Drug Therapy in Lupus Nephropathy
NCT00001212 ·Status: COMPLETED ·Phase: PHASE2
-
Predictors of Remission and Renal Outcomes in Lupus Nephritis in Assuit University Hospitals.
NCT06228222 ·Status: NOT_YET_RECRUITING
-
Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis
NCT00774852 ·Status: COMPLETED ·Phase: PHASE2
-
TF, TFPI and Plasmin as Novel Bio-markers in Early Diagnosis of Lupus Nephritis
NCT04218890 ·Status: UNKNOWN
-
Prediction of Outcome of Lupus Nephritis
NCT02403115 ·Status: UNKNOWN
-
The Efficacy and Safety of Telitacicept and Belimumab in Active Lupus Nephritis in the Real World: a Prospective Cohort Study
NCT05588830 ·Status: UNKNOWN
-
Long-Term Study of Multi-target Therapy as Maintenance Treatment for Lupus Nephritis
NCT01056237 ·Status: COMPLETED ·Phase: NA
-
Per-protocol Repeat Kidney Biopsy in Incident Cases of Lupus Nephritis
NCT04449991 ·Status: RECRUITING ·Phase: NA
-
Pre-emptive Treatments in Lupus Nephritis Patients With Serological Reactivation
NCT04870359 ·Status: COMPLETED ·Phase: NA
-
Identifying New Therapeutic Targets for Lupus Treatment
NCT03921398 ·Status: COMPLETED
-
A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
NCT06064929 ·Status: COMPLETED ·Phase: PHASE1
-
The Expression Profile of New Complement Components in Childhood Lupus Nephritis
NCT05082363 ·Status: UNKNOWN
-
Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis
NCT02453997 ·Status: COMPLETED
-
Anti-ficolin-2 Autoantibodies in Lupus Nephritis
NCT03063281 ·Status: COMPLETED
-
Leflunomide Versus Azathioprine for Maintenance Therapy of Lupus Nephritis
NCT01172002 ·Status: UNKNOWN ·Phase: NA
-
Anti-ficolin-3 Autoantibodies in Lupus Nephritis
NCT02625831 ·Status: COMPLETED
-
Association of Serum Interleukin-33 Levels With Clinical Manifestations in Systemic Lupus Erythematosus
NCT07149402 ·Status: NOT_YET_RECRUITING
-
Fibroblast Growth Factor 21 in Systemic Lupus Erythematosus
NCT06842810 ·Status: NOT_YET_RECRUITING
-
A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.
NCT00377637 ·Status: COMPLETED ·Phase: PHASE3
-
AntiDFS70 Lupus Nephritis
NCT06119763 ·Status: RECRUITING
-
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
NCT07053800 ·Status: RECRUITING ·Phase: PHASE2
-
The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferative Lupus Nephritis
NCT02954939 ·Status: RECRUITING ·Phase: NA
-
T Regulatory Cells IN LUPUS NEPHRITIS
NCT06428539 ·Status: NOT_YET_RECRUITING
-
ACTHar in the Treatment of Lupus Nephritis
NCT02226341 ·Status: TERMINATED ·Phase: PHASE4
-
Daratumumab to Treat Active Lupus Nephritis
NCT04868838 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2